When tirzepatide received FDA approval for weight management, it represented a genuine step forward — 22.5% average weight loss at the highest dose, approaching what’s historically been achievable only with bariatric surgery.
By Dr. Teja V. Surapaneni, MD, MS • Board-Certified Internal Medicine (ABIM) • Licensed NV, WA, OR, WI • May 2026
Tirzepatide is classified as a dual GLP-1/GIP receptor agonist. It activates both the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor — two distinct hormone systems involved in appetite regulation, insulin secretion, and metabolic function.
GLP-1 activation reduces appetite and slows gastric emptying. GIP receptor activation adds a complementary effect: it enhances the metabolic response to GLP-1 and may independently reduce fat storage in adipose tissue. The combination produces a synergistic effect that exceeds what either mechanism achieves alone.
The SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, was the pivotal Phase 3 study for tirzepatide in weight management.
To put that in perspective: a 250-pound person would be expected to lose approximately 56 pounds on average at the highest dose. Secondary endpoints were equally striking: significant reductions in waist circumference, blood pressure, fasting blood sugar, and HbA1c.
Head-to-head data consistently shows tirzepatide producing greater weight loss than semaglutide. The SURMOUNT-5 trial compared the two medications directly and found patients on tirzepatide lost approximately 20% of body weight compared to approximately 14% on semaglutide — a clinically meaningful difference of about 6 percentage points.
That said, the right choice depends on more than efficacy numbers. Individual response varies, tolerability differs between patients, and your physician’s assessment of your specific health profile should guide the decision. Our physicians at YourMD are glad to discuss both options during your consultation.
Tirzepatide for weight management is indicated for adults with:
Contraindications include personal or family history of medullary thyroid carcinoma or MEN2 — the same class-wide contraindications that apply to GLP-1 medications.
The most common side effects are gastrointestinal — nausea, diarrhea, constipation, vomiting — and are most pronounced during dose escalation. Starting at 2.5 mg and titrating slowly over several months significantly reduces the severity. Most patients find side effects manageable and diminishing over time.
YourMD Telehealth’s weight management program routes tirzepatide prescriptions through the manufacturer’s direct pharmacy program, ensuring access to the FDA-approved branded product. Your program includes a physician consultation, individualized dosing protocol, and monthly check-ins.
Free 5-minute screening. No credit card required.
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Consult a qualified physician before starting any prescription medication. Page medically reviewed by Teja V. Surapaneni, MD, MS — Board-Certified Internal Medicine (NV, WA, OR, WI). Last reviewed: May 2026.